Prognostic value of CD56 in patients with acute myeloid leukemia: a meta-analysis.
Extensive studies have investigated the prognostic value of CD56 for patients with acute myeloid leukemia (AML), but the results remained inconclusive. The aim of this meta-analysis is to resolve this controversial issue. A systematic search of PubMed, Embase, Cochrane Library, and CBM was performed to identify studies that assessed the prognostic value of CD56 in AML patients. Pooled hazard ratios (HRs) with 95 % confidence intervals (CIs) for overall survival (OS) and disease-free survival (DFS) and pooled odds ratio (OR) with 95 % CIs for complete remission rate (CRR) and relapse rate (RR) were calculated. Totally, 32 studies with 4074 patients were included. For AML with t(8;21) translocation, CD56 overexpression was associated with shorter OS (HR 2.22; 95 % CI 1.30-3.78) and DFS (HR 2.63; 95 % CI 1.10-6.29) and increased RR (OR 3.29; 95 % CI 1.67-6.48), but did not affect CRR (OR 0.94; 95 % CI 0.49-1.80). For AML with t(15;17) translocation, CD56 overexpression was associated with shorter OS (HR 2.43; 95 % CI 1.66-3.57) and DFS (HR 4.27; 95 % CI 1.15-15.78), increased RR (OR 3.11; 95 % CI 2.01-4.81), and decreased CRR (OR 0.42; 95 % CI 0.25-0.72). For AML as a whole, CD56 overexpression was associated with shorter OS (HR 1.74; 95 % CI 1.38-2.19) and DFS (HR 2.38; 95 % CI 1.87-3.02), increased RR (OR 5.19; 95 % CI 2.84-9.48), and decreased CRR (OR 0.62; 95 % CI 0.41-0.96). This meta-analysis indicated that CD56 overexpression may be an adverse prognostic factor for AML.